SGCB and pulmonary arterial hypertension: Treatments for pulmonary arterial hypertension (PAH, group 1) target three pathways: the prostacyclin pathway, the endothelin pathway, and the nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) pathway [2].